Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Patent metadata

Field	Value
Publication number	US-9908920-B2
Application number	US-201615229970-A
Country	US
Kind code	B2
Filing date	Aug 5, 2016
Priority date	Aug 5, 2015
Publication date	Mar 6, 2018
Grant date	Mar 6, 2018

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

First claim

The invention claimed is:

1. An antibody that specifically binds to a peptide consisting of the amino acid sequence of ALLTFVWKL (SEQ ID NO: 4) or binds to a peptide consisting of the amino acid sequence of ALLTFVWKL (SEQ ID NO: 4) complexed with an MHC molecule.

2. A kit comprising:
(a) a container comprising a pharmaceutical composition containing the antibody of claim 1 in solution or in lyophilized form;
(b) optionally, a second container containing a diluent or reconstituting solution for the lyophilized formulation;
(c) optionally, the peptide having the amino acid sequence of ALLTFVWKL (SEQ ID NO: 4), and
(d) optionally, instructions for (i) use of the solution or (ii) reconstitution and/or use of the lyophilized formulation.

3. The kit according to claim 2 , further comprising one or more of (iii) a buffer, (iv) a diluent, (v) a filter, (vi) a needle, or (v) a syringe.

4. A pharmaceutical composition comprising
the antibody of claim 1 and a pharmaceutically acceptable carrier, and optionally, pharmaceutically acceptable excipients and/or stabilizers.

5. The antibody of claim 1 , wherein said antibody is a polyclonal antibody, a monoclonal antibody, a bi-specific antibody or a chimeric antibody.

6. The antibody of claim 1 , wherein the peptide bound to an MEW molecule is present in a tumor cell.

7. The antibody of claim 6 , wherein the tumor cell is at least one selected from the group consisting of lung cancer, kidney cancer, brain cancer, stomach cancer, colon or rectal cancer, liver cancer, prostate cancer, leukemia, breast cancer, Merkel cell carcinoma (MCC), melanoma, ovarian cancer, esophageal cancer, urinary bladder cancer, endometrial cancer, gall bladder cancer, and bile duct cancer, and other tumors that show an overexpression of a protein comprising a peptide having the amino acid sequence of ALLTFVWKL (SEQ ID NO: 4).

8. The antibody of claim 6 , wherein the tumor cell is prostate cancer.

9. The antibody of claim 1 , wherein the antibody is labeled with a toxin.

10. The antibody of claim 1 , wherein the antibody is labeled with a radionucleotide.

11. The antibody of claim 10 , wherein the radionucleotide is 111 In, 99 Tc, 14 C, 131 C, 3 H, 32 P, or 35 S.

12. The antibody of claim 1 , wherein the affinity value (Kd) of the antibody is less than 1×10 μM.

13. The antibody of claim 1 , wherein the MEW is a MEW class I molecule.

14. The antibody of claim 1 , wherein the MEW is a MEW class II molecule.

15. The antibody of claim 1 , further comprising a binding affinity of below 20 nanomolar.

16. The antibody of claim 1 , wherein the antibody is humanized.

17. The composition of claim 4 , wherein the pharmaceutically acceptable carrier is saline, Ringer's solution, dextrose solution, and/or solid hydrophobic polymer.

18. The composition of claim 17 , wherein the solid hydrophobic polymer is film, liposome, or microparticle.

19. A pharmaceutical composition comprising the antibody of claim 6 and a pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising the antibody of claim 9 and a pharmaceutically acceptable carrier.

21. A pharmaceutical composition comprising the antibody of claim 10 and a pharmaceutically acceptable carrier.

22. A pharmaceutical composition comprising the antibody of claim 13 and a pharmaceutically acceptable carrier.

Assignees

• immatics biotechnology GmbH
• Immatics Biotechnologies Gmbh

Inventors

• Mahr Andrea
• Weinschenk Toni
• Schoor Oliver
• Fritsche Jens
• Singh Harpreet
• Mueller Phillip
• Leibold Julia
• Goldfinger Valentina

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• G01N33/57575

  involving oncogenic proteins · CPC title

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C07K14/47 Primary

  from mammals · CPC title